Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

This week Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in chemistry for developing a process to edit DNA known as CRISPR Cas-9. But the announcement, which comes amid a ...

Genome editing is a group of technologies that serve to help scientists alter an organism’s DNA. The technologies allow for genetic material to be added, removed, or relocated at particular locations ...

CRISPR Therapeutics (NASDAQ: CRSP) stock sank by 15.9% in January, according to data from S&P Global Market Intelligence, amid a surge of bearish momentum impacting the broader market. An assortment ...

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 2.9% in that time frame, underperforming the S&P 500. Will the recent positive trend ...

The gene-editing specialist's stock is now down roughly 64% over the past 12 months. An assortment of risk factors last month led investors to sell stocks lower. Macroeconomic concerns, including high ...